Ana Varela

Ana Varela

Auto-generated profile, based on publicly available information

Ana Varela

Department of Endocrinology, Diabetes and Metabolism, Unidade Local de Saúde de São João, Porto, Portugal

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Case Reports in Endocrinology
Verified
Journal Article
Open access
SRSara Ribeiro
Sara Ribeiro
AVAna Varela
Ana Varela
JQJoana Queirós
Joana Queirós
Resistance to thyroid hormone (RTH) is a rare clinical syndrome characterized by reduced tissue responsiveness to thyroid hormone (TH), typically presenting with elevated TH levels without suppression of thyrotropin (TSH). In most cases, RTH is caused by mutations in the TH receptor beta ( THRB ) gene. While treatment is generally unnecessary due to preserved endogenous compensation, this physiological balance may be disrupted in the presence of compromised thyroidal reserve. We report two unrelated female patients with genetically confirmed RTH and coexisting thyroid disease. The first, an 18‐year‐old with Hashimoto’s thyroiditis, required unusually high doses of levothyroxine to maintain TSH within the normal range and was later diagnosed with RTHβ. The second, a 54‐year‐old with known RTH, developed tachyarrhythmia and amiodarone‐induced hypothyroidism, complicating TH replacement. In both cases, the coexistence of RTH and acquired thyroid disease obscured the clinical picture and posed significant therapeutic challenges. These cases illustrate how superimposed thyroid pathology can destabilize the typically compensated state of RTH, underscoring the importance of maintaining a high index of suspicion in patients with persistent, unexplained thyroid function abnormalities. Early recognition, personalized management, and lifelong follow‐up are essential to ensure optimal outcomes and avoid unnecessary interventions.

1 July 2025 in Endocrinology, Diabetes & Metabolism Case Reports
Verified
Journal Article
Open access
SRSara Ribeiro
Sara Ribeiro
TMTelma Moreno
Telma Moreno
AVAna Varela
Ana Varela
GSGabriela Soares
Gabriela Soares
JQJoana Queirós
Joana Queirós
Summary: X-linked hypophosphatemic (XLH) is the most common inherited form of rickets, caused by inactivating mutations in the PHEX gene. Resultant overproduction of fibroblast growth factor 23 (FGF23) leads to renal phosphate wasting, reduced 1,25-dihydroxyvitamin D (1,25(OH)2D) levels, and impaired bone mineralization. We describe 26-year-old male monozygotic twins with lifelong skeletal deformities, short stature, and chronic bone pain. Despite hallmark features of rickets, both were misdiagnosed for decades and developed progressive functional impairment. Biochemical investigations revealed persistent hypophosphatemia, elevated alkaline phosphatase, reduced tubular maximum reabsorption of phosphate per glomerular filtration rate (TmP/GFR), normal calcium and parathyroid hormone, and inappropriately normal 1,25(OH)2D. Radiographs showed pseudofractures, consistent with osteomalacia. The twins were born from a triplet pregnancy; their dizygotic female sibling remained asymptomatic and biochemically normal. Genetic analysis revealed a novel de novo hemizygous deletion in exon 22 of PHEX, confirming the diagnosis of XLH. Both patients initiated conventional therapy with oral phosphate and calcitriol, resulting in notable clinical improvement, including restored ambulation and reduced pain. To our knowledge, this is the first documented case of phenotypically concordant XLH in monozygotic twins caused by a previously unreported PHEX mutation. The presentation underscores the risk of diagnostic delays in XLH, particularly in sporadic cases without family history, and highlights the value of early molecular testing in complex skeletal disorders. Timely recognition and treatment of XLH are essential to prevent irreversible complications and improve long-term outcomes, even when initiated in adulthood. Learning points: XLH should be considered in patients with skeletal deformities, short stature, and recurrent dental abscesses. Diagnosis is frequently delayed due to variable phenotype and misdiagnosis as nutritional rickets or isolated orthopedic conditions. Biochemical findings of isolated hypophosphatemia with inappropriately normal 1,25(OH)2D levels should prompt evaluation for FGF23-mediated phosphate-wasting conditions. In cases without family history, genetic testing remains essential to confirm XLH and may reveal de novo mutations with clinical and research relevance. Conventional therapy with phosphate and calcitriol may lead to meaningful clinical improvement, including restored mobility, even in adults with long-standing disease. This case contributes to the understanding of genotype–phenotype relationships in XLH, highlighting the potential value of twin studies in elucidating the genetic and non-genetic modifiers of disease expression.